Coverage of Pneumococcal Vaccination in Patients with Respiratory Diseases in the Chelyabinsk Region
https://doi.org/10.31631/2073-3046-2025-24-5-52-58
Abstract
Relevance. Streptococcus pneumoniae (pneumococcus) is one of the main causes of life-threatening infections, which leads to significant morbidity and mortality worldwide. Vaccination provides not only effective protection against pneumococcal infections, complications, and hospitalization, but can also help stabilize the public health system by reducing the incidence of respiratory infections, allowing you to focus on prevention, early detection, and treatment of chronic diseases.
Аim. Аssess the coverage of vaccination against pneumococcal infection in patients with respiratory diseases in the Chelyabinsk region over the past 5 years.
Material and methods. The analysis included patients over the age of 18 with respiratory diseases registered in the Chelyabinsk region, according to Rosstat form No. 12 in the period from 2019–2023. Vaccination coverage was assessed on the basis of information entered into the unified medical information system of the Chelyabinsk region EMIAS BARS, section «Vaccination prevention».
Results. The total coverage of vaccinated patients with respiratory pathology was 8 %, of which 40.8 % were patients with COPD. At the same time, 71.2 % of patients were vaccinated with PCV13, 28.8 % with PPV23. A low percentage of vaccinated patients was registered among patients with other respiratory diseases: with various forms of chronic bronchitis – 2.1 %, bronchial asthma – 3 %, postinfectious bronchiectasis – 14.6 %, interstitial lung diseases – less than 1 %. The highest incidence of communityacquired pneumonia is observed in patients with chronic obstructive pulmonary disease (COPD).
Conclusion. These data indicate a lack of attention to the problem of vaccination against pneumococcal infection and a great potential for increasing coverage of the wider masses of patients, primarily from at-risk groups. Awareness of the population and primary care physicians should be a priority and include various tools aimed at popularizing vaccine prevention.
About the Authors
V. N. Antonov
Federal State Budgetary Educational Institution of Higher Education «South Ural State Medical University2 of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Vladimir N. Antonov – Dr. Sci. (Med.), Professor of the Department of Therapy at the Institute of Additional Professional Education, Chief Researcher atthe Institute of Pulmonology
64 Vorovskiy str., Chelyabinsk, 454092
+7 (351) 742-66-40
G. L. Ignatova
Federal State Budgetary Educational Institution of Higher Education «South Ural State Medical University2 of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Galina L. Ignatova – Dr. Sci. (Med.), Professor, Head of the Department ofTherapy at the Institute of Additional Professional Education, Director at theInstitute of Pulmonology
64 Vorovskiy str., Chelyabinsk, 454092
+7 (351) 742-66-40
References
1. Prins-van Ginkel A.K., Berbers G.A., Grundeken L.H., et al. Dynamics and determinants of pneumococcal antibodies specific to 13 vaccine serotypes in the era preceding vaccination. PLoS One. 2016, January 21;11(1):e0147437. doi: 10.1371/journal.pone.0147437. PMID: 26796783; PMCID: PMC4721864.
2. Bogert D., De Groot R., Hermans P.U. Colonization of Streptococcus pneumoniae: the key to pneumococcal diseases. Lancet Infection Journal, March 2004, 4(3):144–54. doi: 10.1016/S1473-3099(04)00938-7. Identification number: 14998500.
3. Avdeev S. N., Alieva M.Kh., Baranov A.A., et al. Federal clinical guidelines for the vaccination of children and adults against pneumococcal infection. Russian Journal of Preventive Medicine. 2023;26(9-2):3–23. (In Russ.) https://doi.org/10.17116/profmed2023260923
4. Kempling J., Wise A., Liu H.H., et al. Review of evidence on vaccination against pneumococcal infection in adults at increased risk of pneumococcal diseases: identification of risk groups and optimization vaccination coverage in the United Kingdom. Expert Review of Vaccines. 2023, January-December;22(1):785–800. doi: 10.1080/14760584.2023.2256394. Published on September 11, 2023. PMID: 37694398.
5. Lu P. J., Hung MAK, Srivastav A, et al. Surveillance of adult vaccination coverage - United States, 2018. MMWR Review for 2021, May 14;70(3):1–26. doi: 10.15585/mmwr.ss7003a1. PMID: 33983910; PMCID: PMC8162796.
6. Feldman S., Anderson R. Recent advances in epidemiology and prevention of infections caused by Streptococcus pneumoniae. F1000Res. 2020 7;May 9th:F1000 Faculty of Rev-338. doi: 10.12688/f1000research.22341.1. PMID: 32411353; PMCID: PMC7212261
7. Frangos E., Barratt J., Michel J. P., Ekarno F. Vaccination in long-term care: a brief overview. Gerontology. 2024;70(3):241–247. doi: 10.1159/000534998. Date of publication: December 13, 2023. PMID: 38091961.
8. Zavaleta-Monestel E, Hasselmir Hasselmir S, Garcia-Montero J, et al. The impact of vaccination as a strategy to combat bacterial antimicrobial resistance. Cureus. 2024, July 31;16(7):e65840. doi: 10.7759/cureus.65840. PMID: 39219910; PMCID: PMC11363808.
9. Lu EI, Chen H.H., Zhao H., Ozawa S. The impact of pneumococcal conjugate vaccine on health and the economy in the fight against antimicrobial resistance in China. Protocol of the National Academy of Sciences of the USA dated March 30, 2021;118(13):e2004933118. doi: 10.1073/pnas.2004933118. PMID: 33758096; PMCID: PMC8020802.
10. Ignatova G.L., Avdeev S.N., Antonov V.N. Comparative efficacy of pneumococcal vaccination PPV23 and PCV13 in patients with COPD during a 5-year cohort study. Sci Rep 11, 15948 (2021). https://doi.org/10.1038/s41598-021-95129-w
11. Ignatova G.L., Avdeev S.N., Antonov V.N., Blinova E.V. A ten-year analysis of the effectiveness of vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease. Pulmonology. 2023; 33 (6): 750–758 (in Russian). DOI: 10.18093/0869-0189-2023-33-6-750-758
12. Pneumococcal vaccines: WHO position paper, 2012. Available at: http://www.who.int/immunization/position_papers/WHO_PP_pneumococcal_2012_RU.pdf .
13. Order of the Ministry of Health of the Russian Federation No. 1122n dated December 6, 2021 «On approval of the national calendar of preventive vaccinations, the calendar of preventive vaccinations for epidemic indications and the procedure for preventive vaccinations» (with amendments and additions). Available at: https://base.garant.ru/403258640/?ysclid=m3mxw6sm58991314056
14. Briko N.I., Lobzin Yu.V., Baranov A.A., et al. Evaluation of the effectiveness of vaccination programs: main approaches and problems. Pediatric pharmacology. 2014;11(4):8–15. (In Russ.) Available at: https://doi.org/10.15690/pf.v11i4.1057
15. Resolution of the Council of Experts on the use of thiamphenicol glycinate acetylcysteinate in the treatment of community-acquired respiratory infections / S. N. Avdeev, T. I. Garashchenko, N. A. Geppe [et al.] // Clinical microbiology and antimicrobial chemotherapy. – 2021. – VOL. 23, No. 2. – PP. 195–196. – DOI 10.36488/cmac.2021.2.195–196. – ED. UJVVVW.
16. On the National Development Goals of the Russian Federation for the period up to 2030 and for the future up to 2036. Available at: http://www.kremlin.ru/events/president/news/73986
17. Global Strategy for COPD Prevention, Diagnosis and Treatment: report for 2024. Available at: https://goldcopd.org/2024-gold-report/
18. Isturiz R., Webber S. Prevention of pneumococcal pneumonia in adults using a 13-valent pneumococcal conjugate vaccine: CAPiTA, a study on adult immunization against community-acquired pneumonia. An immunotherapeutic vaccine against humans. 2015;11(7):1825–7. doi: 10.1080/21645515.2015.1043502. PMID: 26076136; PMCID: PMC4514202.
19. Briko N.I., Korshunov V.A., Mindlina A.Ya., et al. The role of educational programs in increasing public confidence in vaccination against pneumococcal infection. Epidemiology and vaccine prevention. 2022;21(1):92–97. (In Russ.)https://doi.org/10.31631/2073-3046-2022-21-1-92-97
Review
For citations:
Antonov V.N., Ignatova G.L. Coverage of Pneumococcal Vaccination in Patients with Respiratory Diseases in the Chelyabinsk Region. Epidemiology and Vaccinal Prevention. 2025;24(5):52-58. (In Russ.) https://doi.org/10.31631/2073-3046-2025-24-5-52-58
Views:
11
Email this article 